Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Possible Biomarkers for Cancer Immunotherapy.

Otoshi T, Nagano T, Tachihara M, Nishimura Y.

Cancers (Basel). 2019 Jul 3;11(7). pii: E935. doi: 10.3390/cancers11070935. Review.

2.

Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

Tachihara M, Nishimura Y.

J Thorac Dis. 2019 May;11(Suppl 9):S1289-S1291. doi: 10.21037/jtd.2019.04.76. No abstract available.

3.

Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.

Murakami S, Nagano T, Nakata K, Onishi A, Umezawa K, Katsurada N, Yamamoto M, Tachihara M, Kobayashi K, Nishimura Y.

Intern Med. 2019 Jun 27. doi: 10.2169/internalmedicine.2556-19. [Epub ahead of print]

4.

Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines.

Effendi WI, Nagano T, Tachihara M, Umezawa K, Kiriu T, Dokuni R, Katsurada M, Yamamoto M, Kobayashi K, Nishimura Y.

Cancer Manag Res. 2019 Apr 29;11:3669-3679. doi: 10.2147/CMAR.S193789. eCollection 2019.

5.

Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).

Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K.

Clin Lung Cancer. 2019 Jul;20(4):e492-e494. doi: 10.1016/j.cllc.2019.03.002. Epub 2019 Mar 19.

6.

Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.

Koyama K, Katsurada N, Jimbo N, Tachihara M, Tamura D, Nakata K, Nagano T, Yamamoto M, Kamiryo H, Kobayashi K, Itoh T, Nishimura Y.

Pathol Int. 2019 May;69(5):294-299. doi: 10.1111/pin.12782. Epub 2019 Mar 22.

PMID:
30900377
7.

Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).

Chayahara N, Mukohara T, Tachihara M, Fujishima Y, Fukunaga A, Washio K, Yamamoto M, Nakata K, Kobayashi K, Takenaka K, Toyoda M, Kiyota N, Tobimatsu K, Doi H, Mizuta N, Marugami N, Kawaguchi A, Nishigori C, Nishimura Y, Minami H.

Oncologist. 2019 Jul;24(7):885-e413. doi: 10.1634/theoncologist.2019-0156. Epub 2019 Mar 19.

8.

Non-parallel anti-tumour effects of pembrolizumab: a case of cardial tamponade.

Tachihara M, Yamamoto M, Yumura M, Yoshizaki A, Kobayashi K, Nishimura Y.

Respirol Case Rep. 2019 Jan 31;7(3):e00404. doi: 10.1002/rcr2.404. eCollection 2019 Apr.

9.

Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.

Katsurada M, Nagano T, Tachihara M, Kiriu T, Furukawa K, Koyama K, Otoshi T, Sekiya R, Hazama D, Tamura D, Nakata K, Katsurada N, Yamamoto M, Kobayashi K, Nishimura Y.

Anticancer Res. 2019 Feb;39(2):815-825. doi: 10.21873/anticanres.13180.

PMID:
30711962
10.

ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report.

Ogawa H, Tanaka Y, Tachihara M, Uehara K, Shimizu N, Doi T, Hokka D, Maniwa Y.

Oncol Lett. 2019 Jan;17(1):488-491. doi: 10.3892/ol.2018.9622. Epub 2018 Oct 25.

11.

Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy.

Katsurada N, Tachihara M, Jimbo N, Koyama K, Nakata K, Nagano T, Yamamoto M, Kamiryo H, Kobayashi K, Nishimura Y.

Intern Med. 2019 May 15;58(10):1467-1471. doi: 10.2169/internalmedicine.1982-18. Epub 2019 Jan 10.

12.

Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody.

Kiriu T, Yamamoto M, Nagano T, Koyama K, Katsurada M, Tamura D, Nakata K, Tachihara M, Kobayashi K, Nishimura Y.

In Vivo. 2019 Jan-Feb;33(1):213-220. doi: 10.21873/invivo.11462.

13.

Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.

Nagano T, Tachihara M, Nishimura Y.

Curr Cancer Drug Targets. 2018 Dec 9. doi: 10.2174/1568009619666181210114559. [Epub ahead of print]

PMID:
30526458
14.

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy.

Nagano T, Tachihara M, Nishimura Y.

Cells. 2018 Nov 15;7(11). pii: E212. doi: 10.3390/cells7110212. Review.

15.

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).

Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S.

BMC Cancer. 2018 Oct 3;18(1):946. doi: 10.1186/s12885-018-4819-2.

16.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.

Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.

PMID:
30268482
17.

Bronchoscopy Using Virtual Navigation and Endobronchial Ultrasonography with a Guide Sheath (EBUS-GS) with or without Fluoroscopy for Peripheral Pulmonary Lesions.

Tachihara M, Tamura D, Kiriu T, Tokunaga S, Hatakeyama Y, Shinke H, Nagano T, Nakata K, Hazeki N, Kamiryo H, Kobayashi K, Nishimura Y.

Kobe J Med Sci. 2018 Mar 27;63(4):E99-E104.

18.

Lung squamous cell carcinoma associated with hypoparathyroidism with sensorineural deafness and renal dysplasia syndrome: a case report.

Kojima M, Nagano T, Nakata K, Hara S, Katsurada N, Yamamoto M, Tachihara M, Kamiryo H, Kobayashi K, Usui T, Nishimura Y.

Onco Targets Ther. 2018 Mar 20;11:1595-1599. doi: 10.2147/OTT.S161420. eCollection 2018.

19.

The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.

Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, Tamura D, Tachihara M, Kobayashi K, Nishimura Y.

PLoS One. 2018 Feb 15;13(2):e0193018. doi: 10.1371/journal.pone.0193018. eCollection 2018. Review.

20.

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease.

Kiriu T, Tamura D, Tachihara M, Sekiya R, Hazama D, Katsurada M, Nakata K, Nagano T, Yamamoto M, Kamiryo H, Kobayashi K, Nishimura Y.

Intern Med. 2018 Jan 1;57(1):91-95. doi: 10.2169/internalmedicine.8947-17. Epub 2017 Oct 16.

Supplemental Content

Loading ...
Support Center